Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL22463070 | 0.96 | TDP1 (0.59) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL27753421 | 0.84 | SLC22A6 (0.43) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL7912646 | 0.82 | SLC22A6 (0.47) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL5972500 | 0.80 | CACNA2D1 (0.52) | SLC22A6TDP1SMN1; SMN2MAPTCACNB3 | |
| SCHEMBL28354942 | 0.79 | TDP1 (0.50) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL678102 | 0.79 | SLC22A6 (0.45) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL5077882 | 0.79 | SLC22A6 (0.45) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL5960145 | 0.79 | SMN1; SMN2 (0.48) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL303998 | 0.79 | SLC22A6 (0.53) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 | |
| SCHEMBL21838442 | 0.77 | TDP1 (0.72) | SLC22A6TDP1SMN1; SMN2TSHRGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| EP-3659695-A1 | HIGHLY CROSSLINKED HYBRID POLYIMIDE-SILSESQUIOXANE MEMBRANES | Universiteit Twente (NL) | 2020-06-03 | — | — | EP | disclosed |
| EP-3041599-B1 | HIGHLY CROSSLINKED HYBRID POLYIMIDE-SILSESQUIOXANE MEMBRANES | UNIV TWENTE (NL) | 2019-10-30 | — | — | EP | disclosed |
| US-10052592-B2 | Highly crosslinked hybrid polyimide-silsesquioxane membranes | UNIVERSITEIT TWENTE (NL) | 2018-08-21 | — | — | US | disclosed |
| US-20160199791-A1 | HIGHLY CROSSLINKED HYBRID POLYIMIDE-SILSESQUIOXANE MEMBRANES | UNIVERSITEIT TWENTE (NL) | 2016-07-14 | — | — | US | disclosed |
| EP-3041599-A1 | HIGHLY CROSSLINKED HYBRID POLYIMIDE-SILSESQUIOXANE MEMBRANES | Universiteit Twente (NL) | 2016-07-13 | — | — | EP | disclosed |
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-1765861-A2 | FGFR BINDING PEPTIDES | Enkam Pharmaceuticals A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| EP-1660539-A2 | COMPOUNDS COMPRISING LPA | Enkam Pharmaceuticals A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014623-A9 | COMPOUNDS COMPRISING LPA | — | 2006-03-23 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| US-5316860-A | Waterproofing leather | ROHM AND HAAS COMPANY (US) | 1994-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | SLC22A6 4392/4885TDP1 3935/4885SMN1; SMN2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.